# ATALANTE (NCT02891824)

> ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02891824
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: ARCAGY/ GINECO GROUP
- Conditions: Ovarian Cancer
- Interventions: atezolizumab + avastin + platinum-based chemotherapy; placebo + avastin + platinum-based chemotherapy
- Enrollment: 614
- Primary outcome: Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=atalante-nct02891824